Ruxolitinib plus decitabine intensified conditioning for AML patients having allogeneic stem cell transplant
Official title: Ruxolitinib and Decitabine-Enhanced Conditioning Versus Modified Bu/Cy or BuF Conditioning for the Impact on Relapse of Acute Myeloid Leukemia in First Complete Remission (CR1)After Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter, Prospective Randomized Controlled Trial
Run by Chinese PLA General Hospital · NCT07101588 · Data updated 2026-11-12
This trial will see if adding ruxolitinib and decitabine to standard busulfan-based conditioning before allogeneic HSCT lowers relapse in high‑risk AML patients in first complete remission (CR1).
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 14 Years to 75 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Chinese PLA General Hospital Academic / other |
| Drugs / interventions | Ruxolitinib, chemotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | January 1, 2028 |
| Study ends | December 30, 2028 |
| Registry record updated | March 20, 2026 |
| Trial ID | NCT07101588 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 12–64 with high‑risk AML in first complete remission who have a matched or haploidentical donor, adequate liver and kidney function, no uncontrolled infection, and who can give informed consent.
✕Probably not a fit
Patients with acute promyelocytic leukemia (M3), those without a suitable donor, those outside the age or organ‑function criteria, pregnant patients, or those with uncontrolled psychiatric illness or infections are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized Phase 4 trial compares an intensified conditioning regimen that adds ruxolitinib (step-based dose) and decitabine (20 mg/m²/day) to conventional Bu/Cy or BuF conditioning versus the conventional Bu/Cy or BuF regimen alone in patients with high‑risk AML in CR1 undergoing allogeneic HSCT. Eligible participants are aged 12–64 with appropriate matched or haploidentical donors and adequate organ function. The trial will track relapse rate after transplant, safety (including hematologic toxicity and non‑relapse mortality), and survival outcomes. The approach is based on prior single‑arm data and preclinical rationale that JAK‑STAT inhibition plus hypomethylation may reduce post‑transplant recurrence while maintaining acceptable toxicity.
Why it matters
Potential benefit: If successful, the regimen could lower post‑transplant relapse and improve long‑term survival for high‑risk AML patients undergoing allo‑HSCT.
How similar studies have gone: Prior single‑arm and clinical data suggest decitabine reduces post‑transplant recurrence and ruxolitinib has activity in hematologic malignancies, and small studies of the combination showed promising safety and low short‑term relapse but randomized confirmation is lacking.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\) Acute myeloid leukemia with indications for allogeneic hematopoietic stem cell transplantation, CR1 2) Have HLA-matched sibling donors or haploidentical donors or ≥8/10 HLA-matched unrelated donors 3) The patients' ages range from 12 to 64 years old 4) Liver function: ALT and AST≤2.5 times the upper limit of normal values, bilirubin ≤2 times the upper limit of normal values 5) Renal function: Creatinine ≤ the upper limit of the normal value 6) There are no uncontrollable infections or serious mental and psychological disorders 7) Sign the informed consent form. Exclusion Criteria: * 1\. Patients with acute promyelocytic leukemia (M3) 2. One of the donor and recipient is pregnant 3. Suffering from mental illness or other conditions that prevent one from following the plan.
Where it's running
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Li-ping Dou, Dr.
- Email: lipingruirui@163.com
- Phone: 86-10-66937079
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Graft-versus-host disease after stem cell transplant: testing LBP-MARCO with ruxolitinib
We are testing whether combining LBP-MARCO with ruxolitinib is safe for adults with GVHD after a stem cell transplant.
-
DMR-001 in CALR-mutant myeloproliferative neoplasms
This study tests DMR-001 alone for CALR-mutant essential thrombocythemia or myelofibrosis, and in combination with ruxolitinib for CALR-mutant myelofibrosis.
-
Testing WJ01024 Alone and with Ruxolitinib for Myelofibrosis with Splenomegaly
This early-phase study tests whether WJ01024, by itself or with ruxolitinib, is safe and tolerable and whether it shows signs of activity in adults with myelofibrosis and enlarged spleen.
-
Belumosudil vs. Ruxolitinib for hepatic cGVHD after HSCT
This trial tests whether belumosudil or ruxolitinib works better for hepatic chronic GVHD after a stem cell transplant in people 12 and older.
-
Topical ruxolitinib for adults with pyoderma gangrenosum
This pilot study tests a topical cream of ruxolitinib to see if it helps heal PG ulcers in adults without adding systemic immunosuppressants.
-
Ruxolitinib Cream Plus Corticosteroids for Facial Non-Segmental Vitiligo in Real-World Practice
This real-world study tests whether adding 1.5% ruxolitinib cream to corticosteroids helps people 12 and older with active facial non-segmental vitiligo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.